Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma
Radiation Oncology Journal. 2016;34(4):260-264 
Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy for low- and intermediate-risk prostate cancer
Cancer Treatment Communications. 2016;5:46-50
SHARP hypofractionated stereotactic radiotherapy is low and intermediate-risk prostate carcinoma patients – PSA outcome
European Journal of Cancer. 2017;72:S193-S194
EP-1307: Hypofractionated stereotactic body radiation therapy in low-risk prostate cancer
Radiotherapy and Oncology. 2014;111:S90-S91
Prostate‐specific antigen kinetics following hypofractionated stereotactic body radiotherapy versus conventionally fractionated external beam radiotherapy for low‐ and intermediate‐risk prostate cancer
Asia-Pacific Journal of Clinical Oncology. 2016;12(4):388-395
Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer
Radiation Oncology. 2016;11(1):
Ultra-hypofractionated radiotherapy for low- and intermediate risk prostate cancer: High-dose-rate brachytherapy vs stereotactic ablative radiotherapy
Radiotherapy and Oncology. 2021;158:184-190
Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost and whole pelvic radiotherapy for intermediate- and high-risk prostate cancer
Asia-Pacific Journal of Clinical Oncology. 2016;13(1):21-27
Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer
Seminars in Radiation Oncology. 2017;27(3):268-278
Robotic Stereotactic Body Radiotherapy (SBRT) for Low- and Intermediate Risk Localized Prostate Cancer. Feasibility, Outcome and Toxicity.
. 2022;